Overview

Company Overview

China Biopharma, Inc. (stock symbol CHBO.OB) is a fast growing provider of human vaccine and other pharmaceutical products in China. Through its wholly owned subsidiary, China Biopharma Limited, the Company owns the majority interest of Zhejiang Tianyuan Biotech Co., Ltd. The Company's current products consist of human vaccines and other pharmaceutical products used by general hospital and clinic in China. With its investment and ownership of local Chinese biopharmaceutical companies, the Company plans to build a leading biopharmaceutical product provider in China by leveraging its manufacturing and marketing capabilities and introducing advanced technologies, best products, and experienced management teams.

The Company's current products include human vaccines against influenza (Flu), epidemic hemorrhagic fever (HF), and Japanese encephalitis (JE) with high reputation and market shares among Chinese made vaccines. Through its investment and ownership of leading Chinese bio-pharmaceutical companies, the company plans to build an efficient and profitable biopharmaceutical company in China by introducing the most advanced technologies, best products, and an experienced management team. With a fast growing market, newly completed production facilities, and several other new vaccines in the pipeline, the Company expects to see a steady business growth in the next few years. The company also plans to expand its market beyond China to other developing countries.

The company was founded in October 2000, headquartered now in Hangzhou, China, with its R&D and support centers in both U.S. & China. Founding investors include UTStarcom, Softbank, Mac Wireless, Pacific Century Fund and the Company’s key executives.

The Market

As China becomes one of the world’s largest economies, the domestic demand of high quality biopharmaceutical products has dramatically grown in recently years. Ten years ago, only a few thousands flu shots were used, but in Year 2005, about 20 million flue shots were administrated. We expect this trend to continue for many years in the near future. China has the world’s largest population of 1.4 billion and already ranks No. 4 in the world vaccine market (after US, Germany, and Japan), and there is no doubt that it will be the world’s largest market for biopharmaceutical products.

In the past few years, China has established many successful small local biopharmaceutical companies. It creates a great opportunity for the company to consolidate and become the industry leader.